cetrorelix acetate
Cetrotide

Pharmacologic classification: gonadotropin-releasing hormone (GnRH) analog
Therapeutic classification: infertility agent
Pregnancy risk category X


Available forms
Available by prescription only
Powder for injection: 0.25 mg, 3 mg

Indications and dosages
 Inhibition of premature luteinizing hormone (LH) surges in women undergoing controlled ovarian stimulation. Adults: 3 mg S.C. once during early to middle follicular phase, given when serum estradiol level indicates an appropriate stimulation response, usually on stimulation day 7 (range, days 5 to 9). If human chorionic gonadotropin (hCG) hasn’t been administered within four days after injection, cetrorelix 0.25 mg should be given S.C. once daily until the day of hCG administration. Or, 0.25-mg S.C. multiple dose regimen is given on either stimulation day 5 (morning or evening) or day 6 (morning) and continued once daily until the day of hCG administration.

Pharmacodynamics
GnRH antagonist action: Drug competes with natural GnRH for binding to membrane receptors on pituitary cells, which controls the release of LH and follicle-stimulating hormone.

Pharmacokinetics
Absorption: Drug is rapidly absorbed following S.C. injection. Levels peak 1 to 2 hours after administration.
Distribution: Drug is 86% bound to plasma.
Metabolism: After S.C. administration of 10 mg cetrorelix, small amounts were found in bile samples over 24 hours.
Excretion: Drug is excreted unchanged in urine and as metabolites in bile.

Route Onset Peak Duration
S.C. 1-2 hr 1-2 hr ≥ 4 days


Contraindications and precautions
Contraindicated in patients hypersensitive to cetrorelix acetate, extrinsic peptide hormones, mannitol, GnRH, or any other GnRH analogues. Drug is also contraindicated in women with known or suspected pregnancy or who are breast-feeding.

Interactions
None reported.

Adverse reactions
CNS: headache.
GI: nausea.
GU: ovarian hyperstimulation syndrome.

Effects on lab test results
• May increase ALT, AST, GGT, and alkaline phosphatase levels.

Overdose and treatment
No overdoses have been reported. Single doses up to 120 mg have been well tolerated and have produced no evidence of overdose in patients treated for other indications.

Special considerations
• Drug should be prescribed by clinicians experienced in fertility treatment.
• Dose is adjusted according to patient response.
• When ultrasound shows a sufficient number or follicles of adequate size, hCG is given to induce ovulation and maturation of oocytes.
• To reduce the risk of ovarian hyperstimulation syndrome, don’t give hCG if ovaries show an excessive response to treatment.
• Drug can be administered by patient after proper instruction.
• Pregnancy must be ruled out before starting treatment.
Breast-feeding patients
• It isn’t known if drug appears in breast milk. Don’t use drug in breast-feeding women.

Patient education
• Instruct patient to store 3-mg form at room temperature (77° F [25° C]) and to store 0.25-mg form in refrigerator at 36° to 46° F (2° to 8° C). Advise patient to keep product away from children.
• Instruct patient to report any adverse effect that becomes bothersome.
• Educate patient on the importance of following the regimen exactly as prescribed to achieve optimal results.
• Instruct patient on the proper administration technique, as follows: Wash hands thoroughly with soap and water. Flip off the plastic cover of the vial and wipe the top with an alcohol swab. Attach the needle with the yellow mark to the prefilled syringe. Push the needle through the rubber stopper of the vial and slowly inject the liquid into the vial. Leave the syringe in place and gently swirl the vial until the solution is clear and without residue. Don’t shake. Draw liquid from the vial into the syringe. If necessary, invert the vial and pull the needle back as far as needed to withdraw the entire contents of the vial. Detach the needle with the yellow mark from the syringe and replace it with the needle with the gray mark. Invert the syringe and push the plunger until all air bubbles are gone.
• Tell patient to choose an injection site on the lower abdomen, around the navel. If she receives a multiple-dose (0.25-mg) regimen, tell her to choose a different site each day to minimize local irritation. Instruct her to clean the site with an alcohol swab and gently pinch a skinfold surrounding the site of injection. Instruct her to insert the needle completely into the skin at about a 45-degree angle and, once the needle has been inserted completely, to release her grasp of the skin. Tell her to gently pull back the plunger of the syringe to check for correct positioning of the needle. If no blood appears, tell her to inject the entire solution by slowly pushing the plunger. She should then withdraw the needle and gently press an alcohol swab on the injection site.
• If blood appears when the patient pulls back on the plunger, tell her to withdraw the needle and gently press an alcohol swab on the injection site. Explain that she’ll need to discard the syringe and the drug vial and to repeat the procedure using a new pack.
• Urge the patient to use a syringe and needle only once and then to dispose of them properly. If available, suggest that she use a medical waste container for disposal.

Reactions may be common, uncommon, life-threatening, or COMMON AND LIFE THREATENING.
◆ Canada only
◇ Unlabeled clinical use